International Journal of Thyroidology

Table. 1.

Table. 1.

Progression from Hashimoto’s thyroiditis to Graves’ disease: Case 1

Age TSH μU/mL
(0.3-4)
Free T4 ng/dL
(0.77-1.94)
T3 ng/mL
(0.75-1.9)
TBII IU/L
(0-1.5)
Anti-TPO antibody U/mL
(0-60)
Anti-Tg antibody U/mL
(0-60)
LT dose (mg) MM dose (mg)
7 y, 6 m 5.07 1.33 1.09 Nd* 1.15 167.44 0.05 -
10 y, 5 m 0.005 3.3 Nd 3.07 122.61 509.41 D/C§ 10 b.i.d.
11 y, 2 m 6.30 1.19 1.25 1.40 168.82 Nd D/C 2.5 q.d.
11 y, 10 m 0.02 3.55 2.72 79.34 1626.8 Nd D/C 10 b.i.d.**
12 y, 10 m 0.01 1.75 1.87 Nd Nd Nd D/C 15 b.i.d.
12 y, 11 m 0.01 1.83 2.23 Nd Nd Nd D/C 15 b.i.d.

*Nd: not done

There were no clinical symptoms. After 8 months without medication, she developed goiter and was prescribed levothyroxin.

Laboratory tests were performed at another clinic. Reference ranges are as follows: TSH, 0.4-4.2 μU/mL free T4 0.8-1.9 ng/dL; TBII-positive, ≥1.75 IU/L; anti-Tg Ab-negative, <4.11 U/mL; anti-TPO Ab-negative, <5.61 U/mL.

§D/C: discontinue

In combination with propranolol.

q.d.: q1d, every day

**In combination with propranolol (10 mg b.i.d.), at this time goiter is aggravated.

Int J Thyroidol 2022;15:125-30 https://doi.org/10.11106/ijt.2022.15.2.125
© 2022 Int J Thyroidol